PolyPid Announces Private Placement for Up to 14 Million in Gross Proceeds
PYPD Stock | USD 3.34 0.12 3.47% |
About 61% of PolyPid's investor base is looking to short. The analysis of the overall investor sentiment regarding PolyPid suggests that many traders are alarmed. The current market sentiment, together with PolyPid's historical and current headlines, can help investors time the market. In addition, many technical investors use PolyPid stock news signals to limit their universe of possible portfolio assets.
PolyPid |
Funding Extends Companys Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Expected in Fourth Quarter of 2024 Top-Line Results Anticipated in First Quart
Read at finance.yahoo.com
PolyPid Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards PolyPid can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
PolyPid Fundamental Analysis
We analyze PolyPid's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PolyPid using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PolyPid based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
PolyPid is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
PolyPid Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with PolyPid stock to make a market-neutral strategy. Peer analysis of PolyPid could also be used in its relative valuation, which is a method of valuing PolyPid by comparing valuation metrics with similar companies.
Peers
PolyPid Related Equities
CUE | Cue Biopharma | 11.93 | ||||
PYXS | Pyxis Oncology | 9.84 | ||||
CYTO | Altamira Therapeutics | 7.50 | ||||
INMB | INmune Bio | 3.27 | ||||
ELEV | Elevation Oncology | 3.23 | ||||
ZURA | Zura Bio | 1.67 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
ANIX | Anixa Biosciences | 0.30 | ||||
ARMP | Armata Pharmaceuticals | 2.13 | ||||
INAB | In8bio | 3.23 | ||||
VRPX | Virpax Pharmaceuticals | 4.17 | ||||
VRAX | Virax Biolabs | 4.83 | ||||
KPRX | Kiora Pharmaceuticals | 8.68 |
Complementary Tools for PolyPid Stock analysis
When running PolyPid's price analysis, check to measure PolyPid's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPid is operating at the current time. Most of PolyPid's value examination focuses on studying past and present price action to predict the probability of PolyPid's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPid's price. Additionally, you may evaluate how the addition of PolyPid to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |